CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer

SIMPLE SUMMARY: Abemaciclib, dalpiciclib, palbociclib and ribociclib have all demonstrated significant improvements in progression-free survival in advanced disease. However, to date, abemaciclib and ribociclib are the only CDK4/6 inhibitors shown to improve the overall survival in patients with met...

Descripción completa

Detalles Bibliográficos
Autores principales: Nabieva, Naiba, Fasching, Peter A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046117/
https://www.ncbi.nlm.nih.gov/pubmed/36980649
http://dx.doi.org/10.3390/cancers15061763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046117/
https://www.ncbi.nlm.nih.gov/pubmed/36980649
http://dx.doi.org/10.3390/cancers15061763

Ejemplares similares